LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 2599 | 5383 | 0.4819 | 0.2988 |
BT-20 | OSI-027 | 10 | uM | LJP6 | 72 | hr | 1657 | 2255 | 5383 | 0.4188 | 0.1965 |
BT-20 | WYE-125132 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 2553 | 5383 | 0.4748 | 0.2899 |
BT-20 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 2430 | 5383 | 0.4519 | 0.2530 |
BT-20 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1657 | 5718 | 5588 | 1.0234 | 1.0266 |
BT-20 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1657 | 5585 | 5588 | 0.9996 | 0.9994 |
BT-20 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1657 | 4763 | 5588 | 0.8525 | 0.8258 |
BT-20 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1657 | 4547 | 5588 | 0.8139 | 0.7783 |
BT-20 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4313 | 5383 | 0.8018 | 0.7564 |
BT-20 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1889 | 5383 | 0.3511 | 0.0799 |
BT-20 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1217 | 5383 | 0.2261 | -0.1671 |
BT-20 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1657 | 922 | 5383 | 0.1714 | -0.2941 |
BT-20 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 2517 | 5383 | 0.4683 | 0.2793 |
BT-20 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1552 | 5383 | 0.2891 | -0.0378 |
BT-20 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 2584 | 5383 | 0.4793 | 0.2957 |
BT-20 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 2341 | 5383 | 0.4347 | 0.2245 |
BT-20 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1826 | 5383 | 0.3392 | 0.0581 |
BT-20 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1657 | 1508 | 5383 | 0.2798 | -0.0557 |
BT-20 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4954 | 5383 | 0.9204 | 0.9040 |
BT-20 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4847 | 5383 | 0.8995 | 0.8778 |
BT-20 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1657 | 5575 | 5588 | 0.9979 | 0.9971 |
BT-20 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5847 | 5588 | 1.0463 | 1.0523 |
BT-20 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1657 | 5382 | 5588 | 0.9630 | 0.9568 |
BT-20 | Barasertib | 3.33 | uM | LJP5 | 72 | hr | 1657 | 2292 | 5588 | 0.4103 | 0.2029 |
BT-20 | Barasertib | 1.11 | uM | LJP5 | 72 | hr | 1657 | 2554 | 5588 | 0.4573 | 0.2792 |